Drug intelligence / Profile preview

dupilumab + ruxolitinib

Development stage: Preclinical
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Topical

Overview

Dupilumab + ruxolitinib is a combination therapy used primarily for atopic dermatitis. Dupilumab is a human monoclonal antibody that targets the IL-4 receptor alpha to inhibit IL-4 and IL-13 signaling, addressing underlying type 2 inflammation. Ruxolitinib is a topical JAK1/2 inhibitor that blocks signal transduction via JAK1/2, abrogating STAT-mediated transcription of pro-inflammatory Th2 cytokines. This combination is particularly useful for patients with residual symptoms while on dupilumab monotherapy, especially for facial dermatitis and breakthrough symptoms in skin folds.

Targets

JAK1 (Janus kinase 1)IL4R (Interleukin-4 receptor alpha subunit)JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on dupilumab + ruxolitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dupilumab + ruxolitinib.

Explore the full profile